{"id":"NCT02564211","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)","officialTitle":"A Phase III, Multicenter, Open-label Long-term Treatment Trial to Assess the Safety and Efficacy of Addition of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin Monotherapy in Addition to Diet and Exercise Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-26","primaryCompletion":"2017-03-07","completion":"2017-03-07","firstPosted":"2015-09-30","resultsPosted":"2018-03-14","lastUpdate":"2018-09-04"},"enrollment":77,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Ipragliflozin","otherNames":[]},{"type":"DRUG","name":"Sitagliptin","otherNames":[]}],"arms":[{"label":"Ipragliflozin","type":"EXPERIMENTAL"}],"summary":"This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise therapy.","primaryOutcome":{"measure":"Percentage of Participants Who Experienced at Least 1 Adverse Event (AE)","timeFrame":"Up to 54 weeks","effectByArm":[{"arm":"Ipragliflozin","deltaMin":77.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["34033212"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":77},"commonTop":["Nasopharyngitis","Back pain","Pollakiuria","Thirst","Constipation"]}}